Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma

This study has been terminated.
(Terminated based on safety results from another trial)
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01185548
First received: August 18, 2010
Last updated: April 12, 2011
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2010
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)